Ratings Fisher & Paykel Healthcare Corporation Limited Deutsche Boerse AG
Equities
FPLB
NZFAPE0001S2
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.7 EUR | 0.00% |
|
-1.18% | +26.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 51.73 and 43.1 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.52% | 10.7B | - | ||
-5.60% | 181B | C+ | ||
-4.45% | 101B | C | ||
-4.15% | 67.54B | A | ||
-8.63% | 45.09B | B- | ||
+9.70% | 44.37B | B- | ||
+6.13% | 40.7B | B+ | ||
+15.22% | 29.85B | B | ||
+14.80% | 24.49B | A- | ||
-6.46% | 23.99B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FPH Stock
- FPLB Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited